GNR-097 gene therapy for Duchenne muscular dystrophy in boys

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial has two phases: Phase I uses two increasing dose cohorts to assess tolerability and safety, then Phase II randomizes participants to GNR-097 or placebo to evaluate efficacy, with placebo patients allowed to receive the gene therapy after year one. Eligible participants are ambulatory boys aged 4–9 with DMD, specific DMD gene mutations, high CK levels, and measurable functional activity. Key inclusion also requires stability on steroids and detectable neutral interactions with AAV9. The study is conducted at sites in Belarus and Russia under AO GENERIUM as lead sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent for participation in the trial.
2. Ambulatory boys aged 4-9 years with a documented diagnosis of DMD and clinical manifestations of the disease.
3. A frameshift mutation or nonsense mutation in the DMD gene.
4. Сreatine phosphokinase level \>5000 U/L.
5. Binding antibody titer to AAV9 ≤1:50 \[method: ELISA\].
6. The patient is able to interact with the study physician and perform tests to assess functional activity.
7. Results of functional activity assessment tests at screening (at least in one of the two attempts performed on different days):

   * NSAA ≥22;
   * time to rise from a supine position without using surrounding objects or furniture \<5 sec;
   * 6MWT distance ≥350 m.
8. The patient received oral glucocorticosteroids at a stable dose for ≥12 weeks prior to signing the Informed Consent Form, and it is planned that glucocorticosteroids will be continued during the screening stage and after the patient's inclusion in the study.
9. For patients receiving deflazacort at study entry: switching the patient from deflazacort to prednisolone, in the opinion of the investigator, will not result in a significant deterioration in the patient's health.
10. The patient has been immunized with a vaccine against meningococcal serotypes A, C, Y, W135 (and B, if available) no later than 4 weeks prior to administration of GNR-097/placebo, and the immunization period expires no more than three months after the expected date of administration of GNR-097/placebo.

Exclusion Criteria:

1. Hypersensitivity to any component of GNR-097 or placebo.
2. Patient with cognitive impairment or a sedentary lifestyle that, in the opinion of the investigator, may interfere with the development or manifestation of motor activity.
3. Mutations in exons 8 and/or 9 of the DMD gene; for patients planned for inclusion in Cohort A, additionally: mutations in exons 1-17 and/or 59-71 of the DMD gene.
4. Clinical signs of cardiomyopathy, including left ventricular ejection fraction (Simpson) \<40% based on echocardiography performed during screening.
5. Contraindications to magnetic resonance imaging.
6. History of any autoimmune disease, with the exception of drug-compensated autoimmune thyroiditis.
7. History of tuberculosis; positive or indeterminate result of Diaskintest® TigraTest® or T-SPOT.TB screening.
8. Positive results of tests for hepatitis B, hepatitis C, or HIV screening.
9. Acute infectious diseases that resolved less than 4 weeks before administration of GNR-097/placebo.
10. Immunization with a live attenuated vaccine less than 3 months before administration of GNR-097/placebo OR immunization with any inactivated vaccine less than 4 weeks before administration of GNR-097/placebo.
11. Abnormal laboratory parameters:

    * GGT level is more than three upper limits of normal;
    * total bilirubin \>50.0 μmol/L (except for patients with a confirmed diagnosis of Gilbert's syndrome);
    * creatinine \>160.0 μmol/L;
    * hemoglobin \<80 or \>180 g/L;
    * white blood cell count \>18,500/μL;
    * platelet count below the lower limit of normal.
12. History of taking antisense oligonucleotides, ataluren, gene therapy using vector constructs, or cell therapy.
13. Use of immunosuppressive drugs other than glucocorticosteroids less than 12 weeks prior to signing the Informed Consent Form.
14. Participation in clinical trials less than 6 months prior to signing the Informed Consent Form.
15. Unwillingness or inability of the patient and/or their parent/legal guardian to comply with the protocol requirements and/or the trial procedures.
16. Other diseases or conditions not listed above that, in the opinion of the physician investigator and/or the Sponsor, prevent the patient from participating in the trial, including for safety reasons.

Where it's running

• Republican Scientific and Practical Center Mother and Child
  Minsk, Belarus Recruiting
• Russian Children's Clinical Hospital
  Moscow, Russia Recruiting
• National Medical Research Center for Children
  Moscow, Russia Recruiting
• Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
  Moscow, Russia Recruiting
• Saint Petersburg State Pediatric Medical University
  Saint Petersburg, Russia Recruiting
• Regional Children's Clinical Hospital
  Yekaterinburg, Russia Recruiting

Study contacts

• Study coordinator: Elena I. Zagoruyko, M.D.
• Email: eizagoruiko@generium.ru
• Phone: +7 (926) 344 84 48

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VM100: a nutritional supplement to see if it improves quality of life for boys with Duchenne

  This Phase 2 study tests VM100, a nutritional drink, in boys aged 8 and up with Duchenne muscular dystrophy to see if it can improve quality of life and reduce fatigue.

  Recruiting Phase 2 University of Florida · Gainesville, Florida · NCT07766980

• KER-065 for Duchenne Muscular Dystrophy: safety and potential benefit in boys and men

  This study tests whether KER-065 is safe and can help with symptoms in males with Duchenne muscular dystrophy, including both ambulatory and nonambulatory participants who are on standard care.

  Recruiting at 2 sites Phase 2 Keros Therapeutics, Inc. · Tbilisi and 3 other locations · NCT07704099

• ELEVIDYS safety in Duchenne patients treated after market approval

  This study tests the safety of ELEVIDYS, with sirolimus as a protective treatment, in male children and young adults with Duchenne Muscular Dystrophy who have previously received ELEVIDYS or are eligible to receive it commercially.

  Recruiting Phase 4 Sarepta Therapeutics, Inc. · Houston, Texas · NCT07542314

• SGT-003 gene therapy for ambulant boys and young men with Duchenne muscular dystrophy (IMPACT DUCHENNE)

  This trial will test whether a single intravenous infusion of SGT-003 can help ambulatory boys and young men with Duchenne muscular dystrophy maintain or improve walking and motor function.

  Recruiting at 4 sites Phase 3 Solid Biosciences Inc. · Little Rock, Arkansas and 6 other locations · NCT07160634

• Evaluating Givinostat for Young Children with Duchenne Muscular Dystrophy

  This study is testing a new drug called Givinostat to see if it's safe and how it works in young children aged 2 to 6 with Duchenne Muscular Dystrophy.

  Recruiting at 7 sites Phase 2 Italfarmaco · Brussels and 8 other locations · NCT06769633

• Evaluating respiratory functions and exercise capacity in children with neuromuscular diseases

  This study is trying to see how well children with Duchenne Muscular Dystrophy and Spinal Muscular Atrophy can breathe and exercise compared to healthy kids.

  Recruiting Lokman Hekim University · Ankara, Çankaya · NCT06756633

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.